Latest Headlines

Latest Headlines

After 2014 IPO and recent takeover rumor, medical laser player Lumenis to be acquired for $510M

XIO Group will buy Israeli medical laser player Lumenis for about $510 million in cash. That price tag isn't much of a premium to the company's valuation because a rumor that it would be acquired for about $500 million by China's Fosun Pharma already pushed shares up earlier this year.

Medtronic buys into Arsenal, gets option to purchase the post-surgical foam startup subsidiary

Medtronic has invested in a subsidiary of Arsenal Medical, a startup focused on developing a polymer-based foam to control intra-abdominal bleeding. The device giant gains an option to acquire the subsidiary, Arsenal AAA, upon the achievement of undisclosed milestones. Medtronic also didn't reveal how much it invested in the deal.

Recipharm snags a chemistry-focused CRO amid buyout push

Swedish drug developer Recipharm bought a local CRO for 15.1 million kronor ($6.2 million), fleshing out its chemistry services as it works to expand its share of the European market.

Valeant said to step up talks on potential $800M deal for Egypt's Amoun

Last month, reports said Valeant was eyeing up one of Egypt's largest drugmakers. Now, word has it, those talks have progressed, and the Canadian pharma could be ready to pull the trigger in the coming weeks.

With $2B acquisition of Welch Allyn, Hill-Rom to add diagnostics, patient monitoring

Medical products company Hill-Rom is using its $2 billion acquisition of patient monitoring and diagnostics player Welch Allyn to decrease its reliance on sales of large, acute-care capital equipment--which are highly subject to pressure from macroeconomic changes. 

Allergan extends deal spree with $2.1B Kythera buyout

Actavis may have changed its name to Allergan this week, but nothing has changed about its penchant for dealmaking. The newly bulked-up pharma struck again Wednesday, inking a pact for Kythera Biopharmaceuticals.

Allergan's paying $2.1B for Kythera and its double-chin drug

The freshly rebranded Allergan is planning to spend $2.1 billion on Kythera, maker of an injection to reduce chin fat, in a deal designed to bolster the company's strength in aesthetics.

Big Mylan shareholder Abbott backs Mylan's Perrigo buy

Mylan can breathe a little easier knowing it has support from its largest shareholder in its quest to pick up Perrigo. After all, it's not just a big buyout at stake--but the opportunity to thwart its own unwanted takeover by generics rival Teva.

Pulmatrix hits Wall Street with $10M and a Mylan deal

Respiratory biotech Pulmatrix has completed its nontraditional path to the public markets, closing a merger with upstart Ruthigen to inherit a Nasdaq listing, at the same time banking $10 million and partnering up with generics giant Mylan.

Teva amps up Mylan stake again, winning agenda rights for upcoming annual meeting

In their last letter to Mylan Chairman Robert Coury, Teva's leaders made it explicitly clear: They're proceeding down their takeover path whether Mylan likes it or not. And they took another step forward this week, further hiking Teva's stake in their target.